Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MET/VEGFR2 inhibitor Foretinib · 1 trial · 1 indication
After completion of Phase I portion of the study
Assessed from the time of first dose. Results will be analyzed at time of final analysis
After completion of phase I
| Arm | Type | Description |
|---|---|---|
| Erlotinib | ACTIVE_COMPARATOR | - |
| Foretinib plus Erlotinib | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MET/VEGFR2 inhibitor Foretinib | DRUG | PhaseI and Phase II Arm A: Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I. |
| erlotinib hydrochloride | DRUG | erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I. |
| laboratory biomarker analysis | OTHER | Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting all of the following criteria: * Locally advanced or metastatic disease * Failed 1-2 prior chemotherapy regimen * Must be eligible to receive erlotinib therapy (i.e., patients ...
Top 20 of 76 competitors
MET/VEGFR2 inhibitor Foretinib is a small molecule being studied for the treatment of lung cancer, specifically locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not responded to previous chemotherapy. It is an investigational drug in clinical development and is not approved for any use.
MET/VEGFR2 inhibitor Foretinib targets MET and VEGFR2, as indicated by its name. It is designed to inhibit these receptor tyrosine kinases, which are involved in tumor growth and angiogenesis. The drug is being evaluated in combination with erlotinib in a clinical trial for lung cancer.
MET/VEGFR2 inhibitor Foretinib is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical development for the treatment of lung cancer.
MET/VEGFR2 inhibitor Foretinib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
MET/VEGFR2 inhibitor Foretinib has been studied in one completed clinical trial, identified as NCT01068587. This Phase 1 trial evaluated the drug in combination with erlotinib versus erlotinib alone in patients with locally advanced or metastatic non-small cell lung cancer that had not responded to previous chemotherapy. The trial enrolled 31 participants in Canada.
Yes, MET/VEGFR2 inhibitor Foretinib is also known as GSK1363089. The clinical trial NCT01068587, which tested the drug in combination with erlotinib for lung cancer, used the name GSK1363089 in its title. Both names refer to the same investigational small molecule.